ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
In this study, we found that SPOP and ELK3 are an interacting partner. The interaction between SPOP and ELK3 resulted in increased ELK3 ubiquitination and destruction, assisted by checkpoint kinase-mediated ELK3 phosphorylation. Notably, the modulation of SPOP-mediated ELK3 protein stability affected the c-Fos-induced cell proliferation and invasion of PCa cells. The clinical involvement of the SPOP-ELK3 axis in PCa development was confirmed by an immunohistochemical assay on 123 PCa tissues, with an inverse correlation between increased ELK3 and decreased SPOP being present in ~80% of the specimens. This observation was s...
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Cheol-Jung Lee Heejung Lee Seo Ree Kim Soo-Bin Nam Ga-Eun Lee Kyeong Eun Yang Guk Jin Lee Sang Hoon Chun Han Chang Kang Joo Young Lee Hye Suk Lee Sung-Jun Cho Yong-Yeon Cho Source Type: research
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
Cell Death & Disease, Published online: 17 April 2024; doi:10.1038/s41419-024-06647-0ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance (Source: Cell death and disease)
Source: Cell death and disease - April 17, 2024 Category: Internal Medicine Authors: Cheol-Jung Lee Heejung Lee Seo Ree Kim Soo-Bin Nam Ga-Eun Lee Kyeong Eun Yang Guk Jin Lee Sang Hoon Chun Han Chang Kang Joo Young Lee Hye Suk Lee Sung-Jun Cho Yong-Yeon Cho Source Type: research
Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer
This study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomat...
Source: Asian Journal of Andrology - April 16, 2024 Category: Urology & Nephrology Authors: Shan-Shan Wang Xiao-Jie Bian Jun-Long Wu Bei-He Wang Sheng Zhang Ding-Wei Ye Source Type: research
Evaluating the docetaxel effect in an animal model of polyarthritis
ConclusionDTX reduces the progression and joint destruction in rats induced by Complete Freund ’s Adjuvant which may due to inhibition of PAD4, TNF-α, IL-1β, VEGF, and ACPA. Also, methotrexate exhibited anti PAD4 effect. (Source: Inflammopharmacology)
Source: Inflammopharmacology - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Immune-related LncRNAs scores predicts chemotherapeutic responses and prognosis in cervical cancer patients
ConclusionsAn eight-IRlncRs-based prediction model was identified that has the potential to be an important tool to predict chemotherapeutic responses and prognosis for CC patients. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 14, 2024 Category: Cancer & Oncology Source Type: research
Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
CONCLUSIONS: GSL efficiently protected BMSCs from damage caused by TPF and recovered hematopoiesis.PMID:38610025 | DOI:10.1186/s12906-024-04445-x (Source: Cancer Control)
Source: Cancer Control - April 12, 2024 Category: Cancer & Oncology Authors: Haohui Lin Manhon Chung Jingchun Sun Yi Yang Li Zhang Xiaohua Pan Minghui Wei Sa Cai Yu Pan Source Type: research
Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Gu érin for the treatment of upper tract carcinoma in situ
CONCLUSION: Endoluminal Gem/Doce and BCG have similar oncological outcomes and major adverse event rates in the treatment of UT-CIS. Further prospective evaluation is warranted.PMID:38609747 | DOI:10.1016/j.urolonc.2024.03.012 (Source: Urologic Oncology)
Source: Urologic Oncology - April 12, 2024 Category: Urology & Nephrology Authors: Ian M McElree Sarah L Mott Helen Y Hougen Vignesh T Packiam Michael A O'Donnell Ryan L Steinberg Source Type: research
Cancers, Vol. 16, Pages 1481: EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
In this study, the expression of the tetraspan protein epithelial membrane protein 2 (EMP2) was explored as a predictor of TNBC response to standard chemotherapy. We demonstrate that EMP2 functions as a prognostic biomarker for patients treated with taxane-based chemotherapy, with high expression at both transcriptomic and protein levels following treatment correlating with poor overall survival. Moreover, we show that targeting EMP2 in combination with docetaxel reduces tumor load in syngeneic and xenograft models of TNBC. These results provide support for the prognostic and therapeutic potential of this tetraspan protein...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Ann M. Chan Brian Aguirre Lucia Liu Vei Mah Justin M. Balko Jessica Tsui Navin P. Wadehra Neda A. Moatamed Mahdi Khoshchehreh Christen M. Dillard Meagan Kiyohara Yahya Elshimali Helena R. Chang Diana Marquez-Garban Nalo Hamilton Richard J. Pietras Lynn K. Tags: Article Source Type: research
Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
A triplet chemotherapy regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) is used to treat head and neck squamous cell carcinoma; however, it is toxic to bone marrow mesenchymal stem cells (BMSCs). We p... (Source: BMC Complementary and Alternative Medicine)
Source: BMC Complementary and Alternative Medicine - April 12, 2024 Category: Complementary Medicine Authors: Haohui Lin, Manhon Chung, Jingchun Sun, Yi Yang, Li Zhang, Xiaohua Pan, Minghui Wei, Sa Cai and Yu Pan Tags: Research Source Type: research
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38 (Source: Hand Surgery)
Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38 (Source: Hand Surgery)
Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research
Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer
CONCLUSIONS: For treating prostate cancer, DARO with ADT has good early efficacy, demonstrating prompt and substantial control of PSA levels, with a favorable safety profile.PMID:38590967 | PMC:PMC10999023 | DOI:10.21037/tau-24-96 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Jia Liu Shenghan Wang Yong Yang Shuo Wang Davide Campobasso Yu Guang Tan Qiang Gao Lin Yang Yudong Cao Yongpeng Ji Peng Du Bao Zhang Source Type: research
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer
AbstractPurpose of ReviewThis review aims to explore the evolving landscape of treatments available for metastatic castration-sensitive prostate cancer (mCSPC) patients.Recent FindingsIn less than a decade, evidence was chronologically provided that (1) systemic treatment intensification with docetaxel improves outcomes, including survival, in men with mCSPC, (2) then that these outcomes are also improved when a second-generation androgen receptor pathway inhibitor (ARPI) is combined with androgen deprivation therapy (ADT), and (3) using a “triplet systemic therapy,” which consists in the combination of ADT, an ARPI an...
Source: Current Oncology Reports - April 9, 2024 Category: Cancer & Oncology Source Type: research
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation
CONCLUSION: Our findings suggest that pathology-based risk-adapted omission of adjuvant treatment following NAC + S does not appear to elevate recurrence risk and that NAC may identify patients with favorable tumor biology, yielding a 2-year RFS probability exceeding 95% without adjuvant treatment. Further, the study identifies a patient subset experiencing disease recurrence despite triple modality therapy. Despite limitations, including a retrospective design and modest sample size, the data advocate for controlled NAC + S studies.PMID:38581118 | DOI:10.1002/cam4.7146 (Source: Cancer Control)
Source: Cancer Control - April 6, 2024 Category: Cancer & Oncology Authors: Alisha R Pershad Punam G Thakkar Joseph F Goodman Arjun Joshi Seth M Steinberg Clint T Allen Charalampos S Floudas Source Type: research
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis
CONCLUSIONS: Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.PMID:38582807 | DOI:10.1007/s10147-024-02485-4 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Akihiro Matsukawa Pawel Rajwa Tatsushi Kawada Kensuke Bekku Ekaterina Laukhtina Jakob Klemm Benjamin Pradere Keiichiro Mori Pierre I Karakiewicz Takahiro Kimura Piotr Chlosta Shahrokh F Shariat Takafumi Yanagisawa Source Type: research
